Elafibranor shows positive preliminary results

Elafibranor shows positive preliminary results

Elafibranor, phase 2 trial has shown positive preliminary results in helping those PBC patients who do not respond to UDCA (Urso). In addition, Elafibranor has recently been granted “Breakthrough Therapy Designation” by the FDA as well as “Orphan Drug Designation”. Read more.